IVVD Invivyd, Inc.
Invivyd, Inc., together with its subsidiaries, engages in the research, development, commercialization, and sale of antibody therapies for the prevention and treatment of viral infectious diseases in the United States. T…
Industry Peers
Biotechnology| Headline | Source | Time |
|---|---|---|
Older | ||
 Invivyd Reports Positive Phase 3 LIBERTY Results for VYD2311 and Plans Accelerated Approval Submission Invivyd reported statistically significant Phase 3 safety and tolerability results for VYD2311 compared with an mRNA-based COVID-19 vaccine and said it plans to pursue an Accelerated Approval BLA pending supportive results from its ongoing DECLARATION study. Key Investor TakeawaysInvivyd (NASDAQ:IVVD) said VYD2311 showed significantly lower rates of short-term overall adverse events and systemic adverse events than the mRNA COVID-19 vaccine in the Phase 3 LIBERTY study. | ||
 3 Small-Cap Biotechs With Binary Catalysts on the Calendar Kodiak Sciences, Capricor Therapeutics and Invivyd each face pivotal clinical trial or FDA decisions before the end of 2026 that could significantly move their stock prices. | ||
 Invivyd, Inc. (IVVD) Reports Q2 Loss, Lags Revenue Estimates Invivyd, Inc. (IVVD) delivered earnings and revenue surprises of +6.67% and -13.42%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock? | ||
 RenovoRx, Inc. (RNXT) Reports Q2 Loss, Beats Revenue Estimates RenovoRx (RNXT) delivered earnings and revenue surprises of +37.50% and +25.38%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock? | ||
 SkinHealth Systems Inc. (SKIN) Reports Q2 Loss, Lags Revenue Estimates SkinHealth Systems Inc. (SKIN) delivered earnings and revenue surprises of +50.00% and -1.96%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock? | ||